Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Talazoparib/enzalutamide approved for HRR-mutated mAPMN/S prostate cancer

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at urologytimes.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

The FDA approved the combination of talazoparib and enzalutamide for adults with homologous recombination repair (HRR) gene-mutated metastatic AR-positive prostate cancer, based on the TALAPRO-3 trial showing improved radiographic progression-free survival.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it.

◆ ◆ The Wire takeaway

Your prostate cancer drug targeting HRR mutations now faces new competition with this FDA approval. You need to accelerate differentiation or partnership talks as this combo sets a new treatment standard.

◆ Coverage

4 sources · 26 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalprostate-cancerhrd-mutationtalazoparibenzalutamide